Get App
Download App Scanner
Scan to Download
Advertisement

MedPlus Shares Fall Over 17% After Q1 Net Profit Declines 21%

MedPlus Health Services reported a 21.5% drop in Q1 net profit to Rs 33.2 crore despite 21.8% revenue growth to Rs 1,880 crore, causing shares to fall over 17%.

MedPlus Shares Fall Over 17% After Q1 Net Profit Declines 21%
MedPlus Shares Fall Over 17%
Photo: Freepix
STOCKS IN THIS STORY
Medplus Health Services Ltd
--

Shares of MedPlus Health Services Ltd. plunged more than 17% on Wednesday after the pharmacy retailer reported a decline in Q1FY27 profit and a sharp contraction in operating margin. The stock opened in negative 6.90% with the stock trading at 663.70 apiece and tumbled further to drop over 17%.

The company's consolidated net profit fell 21.5% year-on-year to Rs 33.2 crore in the quarter ended June, as compared to  Rs 42.3 crore in the corresponding period last year. The revenue from operations, however, rose 21.8% to Rs 1,880 crore from Rs 1,543 crore a year earlier.

Operating performance remained subdued, with earnings before interest, tax, depreciation and amortisation (EBITDA) increasing just 2% to Rs 133 crore from Rs 131 crore. The EBITDA margin narrowed to 7.1% from 8.5% in the year-ago quarter, indicating pressure on profitability despite strong revenue growth. The company also approved capital expenditure of Rs 155 crore in Hyderabad.

Medplus Health Q1 Cons

  • Net Profit [RD] 21.5% At Rs 33.2 crore Vs Rs 42.3 crore YoY
  • Revenue [GU] 21.8% At Rs 1,880 crore Vs Rs 1,543 crore YoY
  • EBITDA [GU] 2% At Rs 133 crore Vs Rs 131 crore YoY
  • EBITDA Margin At 7.1% Vs 8.5% YoY
  • Approves Capex Of Rs 155 crore In Hyderabad

MedPlus Health Services Ltd. Share Price Today

MedPlus Health Services Ltd. Share Price Today

MedPlus Health Services Ltd. Share Price Today
Photo Credit: (Photo: NDTV Profit)

The scrip fell as much as 17.71% to Rs 653 apiece on Wednesday at 9:43 am. This compares to a 0.65% fall in the NSE Nifty 50 Index.

It has fallen 26.50% in the last 12 months and 17.79% year-to-date. Total traded volume so far in the day stood at 0.16 times its 30-day average. The relative strength index was at 37.76.

Out of nine analysts tracking the company, all nine maintain a 'buy' rating, according to Bloomberg data. The average 12-month consensus price target of Rs 1,168.38 implies an upside of 73.1%

ALSO READ: Threat Or Opportunity? How Trump's Generic Drug Tariff Plan Could Impact Indian Pharma Stocks

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Listen to the latest songs, only on JioSaavn.com